JP2013517476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013517476A5 JP2013517476A5 JP2012548965A JP2012548965A JP2013517476A5 JP 2013517476 A5 JP2013517476 A5 JP 2013517476A5 JP 2012548965 A JP2012548965 A JP 2012548965A JP 2012548965 A JP2012548965 A JP 2012548965A JP 2013517476 A5 JP2013517476 A5 JP 2013517476A5
- Authority
- JP
- Japan
- Prior art keywords
- protein expression
- cells
- pten
- pten protein
- tumorigenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 20
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 20
- 238000000034 method Methods 0.000 claims 20
- 210000004027 cell Anatomy 0.000 claims 12
- 231100001221 nontumorigenic Toxicity 0.000 claims 10
- 238000005259 measurement Methods 0.000 claims 8
- 210000004881 tumor cell Anatomy 0.000 claims 8
- 229940121935 ErbB tyrosine kinase inhibitor Drugs 0.000 claims 6
- 238000003364 immunohistochemistry Methods 0.000 claims 4
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims 2
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims 2
- 210000002889 endothelial cell Anatomy 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 230000002427 irreversible effect Effects 0.000 claims 2
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical group C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 2
- 229950008835 neratinib Drugs 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 238000003498 protein array Methods 0.000 claims 2
- 238000010186 staining Methods 0.000 claims 2
- 210000002536 stromal cell Anatomy 0.000 claims 2
- 238000001262 western blot Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29461510P | 2010-01-13 | 2010-01-13 | |
| US61/294,615 | 2010-01-13 | ||
| PCT/US2011/020080 WO2011087926A1 (en) | 2010-01-13 | 2011-01-04 | A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015226299A Division JP2016053579A (ja) | 2010-01-13 | 2015-11-19 | 腫瘍を正確に識別し、かつＰＡＮ‐ＥｒｂＢ阻害剤に対する薬物応答を予測するＰＴＥＮタンパク質発現におけるカットポイント |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013517476A JP2013517476A (ja) | 2013-05-16 |
| JP2013517476A5 true JP2013517476A5 (enExample) | 2014-02-27 |
| JP6126382B2 JP6126382B2 (ja) | 2017-05-10 |
Family
ID=43569472
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548965A Active JP6126382B2 (ja) | 2010-01-13 | 2011-01-04 | 腫瘍を正確に識別し、かつＰＡＮ‐ＥｒｂＢ阻害剤に対する薬物応答を予測するＰＴＥＮタンパク質発現におけるカットポイント |
| JP2015226299A Pending JP2016053579A (ja) | 2010-01-13 | 2015-11-19 | 腫瘍を正確に識別し、かつＰＡＮ‐ＥｒｂＢ阻害剤に対する薬物応答を予測するＰＴＥＮタンパク質発現におけるカットポイント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015226299A Pending JP2016053579A (ja) | 2010-01-13 | 2015-11-19 | 腫瘍を正確に識別し、かつＰＡＮ‐ＥｒｂＢ阻害剤に対する薬物応答を予測するＰＴＥＮタンパク質発現におけるカットポイント |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8338456B2 (enExample) |
| EP (1) | EP2524231B1 (enExample) |
| JP (2) | JP6126382B2 (enExample) |
| CA (1) | CA2787048C (enExample) |
| ES (1) | ES2638821T3 (enExample) |
| WO (1) | WO2011087926A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108421044A (zh) | 2005-02-03 | 2018-08-21 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
| BRPI0618042A2 (pt) | 2005-11-04 | 2011-08-16 | Wyeth Corp | usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| CN102641270A (zh) | 2008-06-17 | 2012-08-22 | 惠氏有限责任公司 | 含有hki-272和长春瑞滨的抗肿瘤组合 |
| US8669273B2 (en) | 2008-08-04 | 2014-03-11 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| IL264349B2 (en) | 2009-04-06 | 2024-01-01 | Wyeth Llc | Regimen comprising neratinib for the treatment of cancer |
| NZ599762A (en) | 2009-11-09 | 2014-07-25 | Wyeth Llc | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
| CA2843222A1 (en) * | 2011-07-28 | 2013-01-31 | Genentech, Inc. | Pik3ca h1047r knock-in non-human animal breast cancer model |
| WO2014033367A1 (en) * | 2012-08-30 | 2014-03-06 | Turun Yliopisto | Method of selecting individualized brain cancer therapy |
| US20200157563A1 (en) * | 2017-07-18 | 2020-05-21 | The Broad Institute, Inc. | Methods of producing human cancer cell models and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004044218A2 (en) * | 2002-11-05 | 2004-05-27 | The Regents Of The University Of California | Methods and materials for examining pathways associated with glioblastoma progression |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| CA2566823A1 (en) * | 2003-11-05 | 2005-05-19 | Board Of Regents, The University Of Texas System | Diagnostic and therapeutic methods and compositions involving pten and breast cancer |
| WO2006044748A2 (en) | 2004-10-15 | 2006-04-27 | Monogram Biosciences, Inc. | RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS |
| WO2006116016A2 (en) * | 2005-04-21 | 2006-11-02 | The Regents Of The University Of California | Molecular determinants of egfr kinase inhibitor response in glioblastoma |
| BRPI0618042A2 (pt) | 2005-11-04 | 2011-08-16 | Wyeth Corp | usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica |
| WO2007137187A2 (en) * | 2006-05-18 | 2007-11-29 | Molecular Profiling Institute, Inc. | System and method for determining individualized medical intervention for a disease state |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| NZ600339A (en) * | 2008-02-25 | 2013-12-20 | Nestec Sa | Drug selection for breast cancer therapy using antibody-based arrays |
| BRPI0911451A2 (pt) * | 2008-05-25 | 2019-09-24 | Wyeth Llc | biomarcadores para eficácia medicamentosa de egfr/her/erb |
| CN106153918A (zh) | 2008-10-14 | 2016-11-23 | 卡里斯Mpi公司 | 描绘肿瘤类型生物标志模式和特征集的基因靶和基因表达的蛋白靶 |
-
2011
- 2011-01-04 CA CA2787048A patent/CA2787048C/en active Active
- 2011-01-04 US US12/984,043 patent/US8338456B2/en active Active
- 2011-01-04 ES ES11700467.1T patent/ES2638821T3/es active Active
- 2011-01-04 WO PCT/US2011/020080 patent/WO2011087926A1/en not_active Ceased
- 2011-01-04 JP JP2012548965A patent/JP6126382B2/ja active Active
- 2011-01-04 EP EP11700467.1A patent/EP2524231B1/en active Active
-
2015
- 2015-11-19 JP JP2015226299A patent/JP2016053579A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mercer et al. | Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF | |
| Tian et al. | Autophagy inhibits oxidative stress and tumor suppressors to exert its dual effect on hepatocarcinogenesis | |
| Xu et al. | LZTS2 inhibits PI3K/AKT activation and radioresistance in nasopharyngeal carcinoma by interacting with p85 | |
| Sun et al. | Circular RNA circ-ADD3 inhibits hepatocellular carcinoma metastasis through facilitating EZH2 degradation via CDK1-mediated ubiquitination | |
| Tsuta et al. | Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung | |
| Cáceres-Gorriti et al. | RAN nucleo-cytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 are new prognostic biomarkers in serous epithelial ovarian cancer | |
| Göke et al. | Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck | |
| Hayase et al. | L-type amino acid transporter 1 expression is upregulated and associated with cellular proliferation in colorectal cancer | |
| Liu et al. | High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy | |
| Baumeister et al. | High expression of EpCAM and Sox2 is a positive prognosticator of clinical outcome for head and neck carcinoma | |
| Namisaki et al. | Differential expression of drug uptake and efflux transporters in Japanese patients with hepatocellular carcinoma | |
| JP2016500110A5 (enExample) | ||
| RU2015125575A (ru) | Композиции и способы для лечения злокачественной опухоли | |
| De Thaye et al. | Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma | |
| JP2009537798A5 (enExample) | ||
| Al-Khayal et al. | Identification of the TP53-induced glycolysis and apoptosis regulator in various stages of colorectal cancer patients | |
| Ciesielska et al. | Expression of cell cycle-related proteins p16, p27 and Ki-67 proliferating marker in laryngeal squamous cell carcinomas and in laryngeal papillomas | |
| Sawicka et al. | The specificity and patterns of staining in human cells and tissues of p16INK4a antibodies demonstrate variant antigen binding | |
| Wang et al. | The role of MAPK signaling pathway in the Her-2-positive meningiomas | |
| JP2015521728A5 (enExample) | ||
| Zheng et al. | Clinicopathological significance of Sox2 expression in patients with breast cancer: a meta-analysis | |
| JP2011511271A5 (enExample) | ||
| Mendelsohn et al. | Snail as a novel marker for regional metastasis in head and neck squamous cell carcinoma | |
| Silvestri et al. | Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations | |
| You et al. | Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma |